Background: To determine whether pulmonary metastasectomy or the addition of ifosfamide/dacarbazine to a doxorubicin-containing regimen offers a survival benefit to adult patients with metastatic leiomyosarcoma.
introduction
Soft tissue sarcomas constitute a heterogeneous group of rare cancers, accounting for >50 different histological subtypes [1] . For decades, all subtypes of soft tissue sarcomas have been merged into the same retrospective analyses or clinical trials [2] . If soft tissue sarcomas are considered as one single disease, the probability of response to chemotherapy has been sadly low, not exceeding 20%-40% [2] . Median survival is generally <12 months, although long-term survival has been described in a limited number of cases [3] . Recent data have clearly demonstrated the dramatic response rate exhibited by some histological subtypes exposed to specific histology-tailored treatments [4, 5] . To better analyze the impact of each chemotherapy agent or combination, we now need to partition and reframe the study of soft tissue sarcoma according to histological subtypes.
Leiomyosarcomas (LMS) account for between 5% and 10% of soft tissue sarcomas [2, 3, 6, 7] . LMS are most frequent in the fifth and sixth decades of life. They can arise at any anatomical site but two locations are more frequent in comparison with other histological subtypes: the uterus and retroperitoneum. There is no well-established risk factor. The optimal local treatment of LMS requires well-planned wide surgical excision followed by radiotherapy in most cases [6] . Despite this local treatment, the rate of metastatic relapse is 40% at 5 years [7] . This constitutes, in most cases, an incurable condition usually treated with doxorubicin-containing chemotherapy [3] . However, the impact of combination regimens containing ifosfamide [8] or dacarbazine [9] [10] [11] [12] or of metastasectomy [13, 14] remains the subject of debate. LMS was for a long time considered to be a relatively chemoresistant subtype. Nevertheless, the distinction between LMS and gastrointestinal stromal cell tumors (GISTs, well known to be resistant to chemotherapy) is relatively recent, casting doubt on previous data underpinning such resistance.
In light of these facts, we investigated the respective impact of dacarbazine, ifosfamide and metastasectomy on progressionfree survival (PFS) and overall survival (OS) among patients with metastatic LMS receiving a doxorubicin-based front-line regimen. This made it necessary, firstly, to identify the prognostic factors for PFS and OS and then to adjust the analysis to these factors. To this end, we compiled a database of 147 patients treated in six tertiary cancer centers of the French Sarcoma Group.
patients and methods
patients From September 1998 to September 2008, 147 consecutive chemotherapynaive adult patients ( ‡18 years old) with a metastatic LMS were admitted to one of the following six comprehensive cancer centers: Centre Oscar Lambret (Lille), Institut Bergonié (Bordeaux), Centre George-Franc xois Leclerc (Dijon), Centre René Gauducheau (Nantes), Hô pital Saint-Louis (Paris) and Hô pital La Timone (Marseille). Clinical and pathological data were collected by reviewing the medical records at each institution. The histological diagnoses were reviewed for all specimens by one of the expert pathologists of the French Sarcoma Group. In all cases, the diagnosis of LMS was confirmed, according to the World Health Organization classification of tumors [1] . Gastrointestinal stromal tumors were excluded. The histological grade was determined according to the Fédération Nationale de Centres de Lutte Contre le Cancer grading system [15] .
statistical analysis
The statistical analysis of baseline demographics and clinical outcomes was based on all available data up to the cut-off date of 24 December 2008. The continuous variables were dichotomized according to their median value. OS was defined as the interval between the first cycle of chemotherapy and death or last follow-up. PFS was defined as the interval between the first cycle of chemotherapy and observed disease progression or last follow-up. Survival curves were estimated using the Kaplan-Meier method and comparisons were done with the log-rank test. Variables associated with a P value <0.05 under univariate analysis were included in multivariate analysis. Multivariate analysis and adjustment to prognostic factors were carried out by Cox regression. The analysis of treatment parameters that influence PFS was unadjusted because we did not identify an independent prognostic factor. The analysis of treatment parameters that influence OS was adjusted to an independent prognostic factor. Analyses were carried out using SPSS 14.0 statistical software (SPSS Inc., Chicago, IL).
results patients
The study population consisted of 147 patients (106 women and 41 men). The median age was 60 years (range 34-89 years). Their characteristics are described in Table 1 . No patient had clinical evidence of a predisposing genetic condition, such as neurofibromatosis. Only three LMS arose in irradiated fields (2%). In 88 cases, there was no persistent disease or relapse at the primary site. No patient had previously received adjuvant chemotherapy. The median interval between initial diagnosis and metastatic relapse was 12 months (range 0-139 months).
treatment delivery
All patients received a doxorubicin-based regimen as front-line treatment. This front-line regimen also contained ifosfamide in 78 cases (53%) or dacarbazine in 56 cases (38%). A total of 73 patients (49%) received granulocyte colony-stimulating factors. The median number of cycles was 4 (range 1-10). The median dose intensity of doxorubicin was 57 mg/m 2 /3 weeks in the whole cohort. In all, 68 patients (46%) received at least 60 mg/ m 2 /3 weeks of doxorubicin. The median dose intensity of doxorubicin was 65 mg/m 2 /3 weeks in patients receiving monotherapy and 52 mg/m 2 /3 weeks in patients receiving combination therapy (P = 0.003). At the end of this front-line chemotherapy, 36 patients (24%) underwent metastasectomy (lung metastasis in all cases). At the time of disease progression, 89 patients (60%) received second-line chemotherapy. The most commonly administered second-line regimens were a docetaxel (Taxotere, Sanofi-Aventis, France) and gemcitabine combination (25 cases, 30%), gemcitabine alone (16 cases, 18%), dacarbazine alone (five cases, 6%) and ecteinascidin-743 (three cases, 3%).
progression-free survival
Under a doxorubicin-containing regimen, median PFS was 6.5 months (range 1-41 range, Figure 1 ). Under univariate analysis, six variables influenced PFS (Table 2) : grade 1 (P = 0.033), primary in the lower limb (P = 0.021), absence of lung metastases (P = 0.028), absence of liver metastases (P = 0.005), absence of other metastases (P = 0.042), and performance status zero (Eastern Cooperative Oncology Group) or one (P = 0.007). Under multivariate analysis, no such variable was retained as an independent prognostic factor for PFS Rare primaries were pelvis (five), lung (lung), inferior vena cava (four), small intestine (two), peritoneum (two), pulmonary artery (one), mediastinum (one), penis (one) and unknown primary (one).
original article Annals of Oncology (Table 3 ). The sole treatment parameter that improved PFS was planned doxorubicin dose >60 mg/m 2 /3 weeks [hazard ratio (HR) = 0.13, 95% confidence interval (CI) 0.09-0.75, P = 0.023, Table 3 ].
overall survival
Median OS was 17 months (range 1-115 months, Figure 2 ). The univariate analysis retained the following potential prognostic factors: absence of local relapse (P = 0.008), grade 1 (P = 0.048), interval between initial diagnosis and metastatic relapse >12 months (P = 0.001) and performance status more than 1 (P = 0.016). Under multivariate analysis, the interval between initial diagnosis and metastatic relapse appeared to be the sole independent prognostic factor for OS (Table 3) . After adjustment, multivariate analysis showed that complete metastasectomy improved PFS [HR = 0.52 (95% CI 0.38-0.87), P = 0.012], whereas the addition of ifosfamide worsened OS [HR = 1.42 (95% CI 1.05-2.10), P = 0.028, Table 3 ].
discussion
We formed a homogeneous group of metastatic and chemotherapy-naive LMS patients treated with a doxorubicincontaining regimen. In our experience, uterine and retroperitoneal LMS display similar behavior as compared with other primaries. The general characteristics of our study population are consistent with previously reported data in terms of OS or PFS [2, 3, 16] .
Doxorubicin remains the cornerstone of the management of metastatic soft tissue sarcoma. In our study, a dose of doxorubicin maintained at 60 mg/m 2 /3 weeks led to longer PFS, but this was not translated into better OS. Dacarbazine yielded promising results in initial phase II trials, with LMS accounting for a large percentage of the responding patients [10] . In consequence, dacarbazine has frequently been associated with doxorubicin for the treatment of all histological subtypes of metastatic soft tissue sarcoma and especially Annals of Oncology original article metastatic LMS. Nevertheless, dacarbazine did not influence PFS or OS in our study. Several clinical trials have also demonstrated the lack of superiority of a dacarbazinedoxorubicin combination in metastatic soft tissue sarcomas [9, 11, 12] . Ifosfamide is the third agent having demonstrated efficacy on metastatic soft tissue sarcoma. In our study, ifosfamide did not favorably influence the outcome of metastatic LMS and the combination could be associated with worsened outcome, probably due to increased toxicity. These findings were also consistent with published randomized trials investigating the benefit of the addition of ifosfamide for the treatment of all histological subtypes of metastatic soft tissue sarcomas [8, [17] [18] [19] . Despite this evidence, combination chemotherapy remains widely administered. In our study, only 42 patients (36%) received mono-chemotherapy. Monotherapy was associated with better dose intensity in doxorubicin (65 versus 52 mg/m 2 /3 weeks, P = 0.003). We have known since the 1970s that response rate depends on the scheduled dose [20] . Combination chemotherapy regimens are associated with a greater risk of decrease in dose intensity. We certainly need to better explore the maintenance of dose intensity in doxorubicin rather than suboptimal under-dosed combinations. The literature data on metastasectomy in the context of metastatic soft tissue sarcoma are very sparse. The median OS after pulmonary resection was about 18-28 months in studies conducted in the 1960-1980s [21, 22] and possibly better in recent studies conducted in the context of better imaging methods such as thin-cut computerized tomography and positron emission tomography [13, 14] . Nevertheless, the role of this type of surgery had not been investigated in a prospective trial. In our study, 28 patients (24%) underwent metastasectomy at the end of first-line chemotherapy, irrespective of the anatomical site of the metastases. Twenty metastasectomies were pulmonary (71%). These metastasectomies were considered to be complete by the surgeon in 18 cases (64%). The metastasectomies were associated with a better outcome. Yet this finding could be the result of the patient selection process rather than the surgical procedure. Establishing the benefit of metastasectomy would require further randomized clinical trials.
The results of the present study must be interpreted with caution due to its retrospective nature and relatively few cases. For example, we did not collect precise data on the treatment of the primary site (adjuvant radiotherapy, quality of margins, etc.) that could influence the outcome. In this series, the patients did not receive previous adjuvant chemotherapy as is recommended in France, in view of the negative results of recent large phase III trials [23] . Moreover, the precise calculation of dose intensity of dacarbazine and ifosfamide was not feasible due to the retrospective nature of the study. Nevertheless, to our knowledge, there is no similar study in the original article Annals of Oncology medical literature. Our study population was relatively homogeneous and the key findings were consistent with previous reports. LMS is one of the most frequent histological subtypes of soft tissue sarcomas. This subtype seems to be particularly sensitive to recently investigated agents, such as temozolomide [24] , trabectedin [25] , gemcitabine [26] or a gemcitabine-docetaxel combination [5, 27] . These new options need to be compared with doxorubicin alone in further studies specifically enrolling LMS. Nowadays, as GIST is clearly individualized, LMS appears to be as chemosensitive as the other main histological subtypes of soft tissue sarcoma.
To conclude, doxorubicin remains the cornerstone of the management of metastatic LMS. The role of metastasectomy needs to be better analyzed, taking prognostic factors into account. Despite the fact that combinations are widely administered, no evidence supports the benefit of regimens containing dacarbazine or ifosfamide. 
